10.82
+5.87%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Vicore Pharma Holding
Its shares trade on Nasdaq Stockholm under the ticker VICO.ST. It has been listed since 10 December 2015. In the fiscal year to 31 December 2024, it reported revenue of SEK 109.3m and a net loss of SEK 168.6m. At that date it held total assets of SEK 1.20bn and shareholders' equity of SEK 1.13bn.
Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2015-12-10. The firm's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The firm is a wholly owned subsidiary of Mintage Scientific AB.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 10 Dec 2015
- Employees
- 26
- Website
- vicorepharma.com ↗
Leadership
Pay as last reported
- Mr. Hans SchikanIndependent Chairman of the Board, since 2018SEK 1.0m
- Mr. Ahmed MousaChief Executive OfficerSEK 8.3m
- Mr. Hans JeppssonChief Financial Officer
- Ms. Nina CarlenChief Administrative Officer
- Mr. Johan RaudChief Scientific Officer
- Ms. Megan RichardsVice President - Investor Relations, Communications and Portfolio Strategy
- Ms. Helen BarkerVice President and Head of CMC
- Mr. Mikael NygardVice President - Operations and Corporate Strategy
- Ms. Elin RosendahlVice President - Clinical Development
- Mr. Jimmie HofmanVice President - Business Development
- Ms. Johanna GraensProgram Director - Early Development
- Mr. Bertil LindmarkChief Medical Officer
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 62
- Environment
- 70
- Social
- 43
- Governance
- 72
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Vicore Pharma's focus on interstitial lung diseases with 26 employees demonstrates efficient resource allocation.
- The company's portfolio includes small molecules for anti-inflammation and cardiovascular disease indications.
- Mintage Scientific AB wholly owns Vicore Pharma, providing stable financial backing.
Weaknesses
- Vicore Pharma's small team of 26 employees limits research and development capacity.
- The company's IPO on 10 December 2015 indicates limited market experience.
- Vicore Pharma's focus on niche medical areas may restrict broader market reach.
Opportunities
- Expanding into nerve generation indications could leverage Vicore Pharma's existing small molecule portfolio.
- The growing market for interstitial lung disease treatments presents significant growth potential.
- Collaborations with larger pharmaceutical firms could enhance Vicore Pharma's development capabilities.
Threats
- Competition in the biotechnology sector for interstitial lung disease treatments is intensifying.
- Regulatory hurdles for new drug approvals in the Health Care sector may delay product launches.
- The small size of Vicore Pharma may hinder its ability to compete with larger pharmaceutical companies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.